Core Insights - The company, Kelun Pharmaceutical, announced that AI has improved the fermentation levels in production processes, surpassing the levels achieved without AI [1] - The production line for thiocyanate erythromycin is fully integrated with the AI system, with plans to quickly incorporate AI into cephalosporin and penicillin production lines [1] - Experimental results indicate that under the same material input, the average yield of AI-controlled fermentation tanks exceeds that of the control group by approximately 3% to 5% [1] - As batch numbers increase and iteration speeds accelerate, overall fermentation levels are expected to improve further [1] - In the field of synthetic biology, AI has significantly enhanced enzyme modification efficiency and activity, greatly improving research and development efficiency [1] - The company is gradually applying AI to various research and development tools, with expectations for AI to play a larger role in the R&D phase in the future [1]

证券日报网讯科伦药业（002422）9月1日发布公告，在公司回答调研者提问时表示，虽然输液和仿制药 板块面临需求回落，但公司持续加强准入、业务拓展和重点品种布局，为未来结构优化和放量创造了条 件。抗生素板块需求端目前趋于稳定，尽管价格波动，但公司成本优势明显。同时，川宁生物 （301301）通过人工智能在降本方面取得实质性进展，相关成果也有望推广至其他产品线。合成生物板 块目前有多个产品逐步放量，今年是合成生物学销售元年，销售提升将会有一个积累的过程。创新药板 块研发进展顺利，商业化体系日趋成熟，若医保谈判等顺利推进，已获批及即将获批品种有望在明年快 速放量。今年是调整修复之年，公司会调整蓄势，为恢复快速增长做好准备。 ...

科伦药业大输液业务曾依靠大规模、低成本制造维持优势。但受国家"限抗令"和"合理用药"等政策影响，门诊输液率被严格控制，直接压缩了行业需求；另 一方面，集采常态化让输液产品价格持续承压。 8月28日，科伦药业公布2025年半年报。2025年上半年，科伦药业实现营业收入为90.8亿元，同比下降23.2%；实现归母净利润为10.0亿元，同比下降 44.4%；实现扣非归母净利润为9.85亿元，同比下降43.8%。 此外，科伦药业的经营现金流净额为11.9亿元，同比下降53.0%。 其中第二季度，科伦药业实现营业收入为46.9亿元，同比下降16.3%；归母净利润为4.16亿元，同比下降46.2%；扣非归母净利润为4.21亿元，同比下降 44.7%。 8月29日，智通财经从科伦药业业绩沟通会了解到，2025年上半年，科伦药业面临行业性困难，主要受流感等传染病发病率下降、医保控费等宏观环境影 响。 不过，对当前的科伦药业而言，最大的挑战依然来自集采。智通财经了解到，从目前执行的省级带量采购以及国家集采情况来看，科伦药业整体产品销量确 实有所增长，但结构优化仍未完全抵消价格下滑带来的压力。 从业务结构上来看，科伦药业目前采用 ...

每经AI快讯，科伦药业（SZ 002422，收盘价：36.46元）发布公告称，2025年8月29日下午，科伦药业 接受东海证券等投资者调研，科伦药业副总经理兼财务总监赖德贵等参与接待，并回答了投资者提出的 问题。 每经头条（nbdtoutiao）——个人消费贷贴息明日开闸！贷30万元最多可享贴息3000元，一文读懂→ 2025年1至6月份，科伦药业的营业收入构成为：医药制造业占比89.66%，研发项目占比7.01%，其他业 务占比3.33%。 （记者 胡玲） ...

四川科伦药业股份有限公司投资者关系活动记录表 编号：0075 | | √特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | | | □其他：电话调研 | | | 东海证券、东方证券、东吴证券、广发证券、国联民生证券、国盛证券、 | | 参与单位名称 | 国泰海通证券、国信证券、华安证券、华泰证券、华源证券、杰富瑞、开 | | 及人员姓名 | 源证券、摩根士丹利、瑞银证券、西部证券、信达证券、兴业证券、银河 | | | 证券、中信建投、中信证券等机构和投资者共 154 人次 | | 时间 | 2025 年 8 月 29 日下午 | | 地点 | 线上 | | | 科伦药业副总经理兼财务总监赖德贵先生、副总经理兼董事会秘书冯昊先 | | | 生、科伦药业销售负责人戈韬先生、科伦药物研究院总经理赵栋先生；科 | | 上市公司接待 人员姓名 | 伦博泰副总经理兼首席战略官冯毅先生、科伦博泰首席财务官兼董事会秘 | | | 书周泽剑先生；川宁生物副总经理兼销售总监姜海先生、川宁生物副总经 | ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, with a focus on the challenges faced in its infusion, generic drugs, and raw materials segments, while highlighting growth opportunities from innovative product launches [1][2]. Revenue and Profit Summary - The company’s total revenue for the first half of 2025 was 9.083 billion yuan, a decrease of 23.2% year-on-year, with a net profit attributable to the parent company of 1.001 billion yuan, down 44.41% [1]. - In Q2 alone, revenue was 4.693 billion yuan, reflecting a year-on-year decline of 16.3%, and net profit was 416 million yuan, down 46.2% [1]. Business Segment Performance - **Infusion Segment**: Revenue was 3.750 billion yuan, a decline of 19.65% year-on-year. The company is transitioning to fully closed infusion systems, with the market share of closed infusion products increasing by 0.39 percentage points [2]. - **Non-Infusion Formulations**: Revenue reached 1.955 billion yuan, down 3.18% year-on-year. The sales of plastic water injections decreased by 11.96% due to reduced demand for glucose injections and the failure to win bids in national procurement [2]. - **Intermediate and Raw Materials**: Revenue from antibiotic intermediates and raw materials was 2.282 billion yuan, down 30.29% year-on-year, primarily due to market demand fluctuations [2]. International Business - The company achieved overseas revenue of 1.130 billion yuan, a decline of 39.69% year-on-year, mainly due to a decrease in overseas licensing income [3]. R&D and Innovation - The company is advancing its R&D pipeline with a dual focus on core business and innovative exploration. The innovative product Jiatailai has been launched, and further exploration for its use in treating various solid tumors is ongoing [3]. - Collaborations with Merck are progressing on 14 clinical studies for sac-TMT as a monotherapy or in combination with other drugs for multiple cancer types [3]. Investment Outlook - The company’s infusion and raw material intermediate businesses are expected to reach a bottom, with ongoing progress in the pipeline and accelerated sales of innovative products. Projected net profits for 2025-2027 are 1.675 billion, 2.248 billion, and 2.716 billion yuan, with year-on-year growth rates of -43%, 34%, and 21% respectively [4].

证券代码：002422 证券简称：科伦药业 公告编号：2025-063 四川科伦药业股份有限公司 关于公司 2025 年度中期利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 第八届董事会第八次会议、第八届监事会第七次会议审议通过了《关于公司 2025 年度中期利润分配预案的议案》。现将相关情况公告如下： 二、利润分配方案的合法性、合规性和合理性 本次利润分配预案符合《公司法》《上市公司监管指引第 3 号——上市公司 现金分红》《公司章程》及《未来三年股东回报规划（2024-2026）》等规定， 符合公司确定的利润分配政策、股东回报规划，该方案合法、合规。本次利润分 配预案充分考虑了公司 2025 年半年度盈利状况、公司未来发展资金需求以及股 东投资回报等综合因素，符合公司和全体股东的利益，具备合理性。该分配方案 的实施不会对公司日常经营造成不良影响。 三、履行决策程序情况及意见 （一）董事会审议程序 对，0 票弃权审议通过了《关于公司 2025 年度中期利润 ...

Core Viewpoint - The article highlights the strategic adjustments made by prominent fund managers in response to the market's structural characteristics, focusing on sectors like AI, innovative pharmaceuticals, and consumer goods, while also indicating a clear divergence in the consumer sector's performance [2][3][4]. Group 1: Fund Manager Strategies - Prominent fund managers have collectively increased their positions in high-growth sectors such as AI and innovative pharmaceuticals while making structural adjustments within the consumer sector [2]. - The technology and pharmaceutical sectors have emerged as core allocation directions, with significant investments in companies like BYD (increased by 184.78%) and Alibaba (increased by 161.10%) [2]. - Fund managers are focusing on "hard technology" in the tech sector, with AI computing and robotics becoming key investment areas [4]. Group 2: Consumer Sector Dynamics - The consumer sector has shown significant structural differentiation, with fund managers displaying contrasting attitudes towards traditional liquor and new consumption trends [3]. - Some fund managers have increased their holdings in traditional liquor stocks like Wuliangye and Moutai, while others have reduced their positions in these stocks, indicating a shift towards new consumption opportunities [3][4]. - The performance of consumer companies has influenced fund adjustments, with companies like Yili achieving strong revenue growth while others like Yanghe experienced profit declines [4]. Group 3: Future Outlook - Looking ahead to the third quarter, there is optimism regarding the innovative pharmaceutical sector, driven by global collaborations and anticipated clinical data disclosures [5]. - The consumer healthcare sector is expected to continue benefiting from rising health awareness among residents, with demand for home medical devices projected to grow steadily due to an aging population [5]. - The overall economic environment is seen as favorable for investment, although structural pressures may persist, with policies aimed at reducing excessive competition likely to improve corporate profitability [5].

格隆汇8月28日丨科伦药业(002422.SZ)公布2025年半年度报告，上半年公司实现营业收入90.83亿元，同 比下降23.20%；归属于上市公司股东的净利润10.01亿元，同比下降44.41%；归属于上市公司股东的扣 除非经常性损益的净利润9.85亿元，同比下降43.79%；基本每股收益0.63元；拟向全体股东每10股派发 现金红利1.26元(含税)。 ...

四川科伦药业股份有限公司 董事会环境、社会及治理（ESG）委员会实施细则 第五条 委员会任期与董事会成员任期一致，委员任期届满，连选可以连 任。期间如有委员不再担任公司董事职务或出现不适宜担任委员的情形，自动失 去委员资格，并由董事会根据上述第三至第四条的规定补足委员人数。 委员辞职导致委员会中独立董事占比不符合本实施细则第三条规定的，在新 的委员就任前，原委员仍应继续履行职责，法律法规、深圳证券交易所或者《公 司章程》另有规定的除外。 （2025年8月修订） 第六条 委员会设主任委员（召集人）一名，由董事长提名具有管理公司 环境、社会及治理专业能力的董事担任。 第一章 总则 第七条 委员会下设 ESG 工作组，负责委员会日常事务及执行委员会决议， 包括但不限于筹备委员会会议、执行公司环境、社会及治理的具体工作。 第一条 为进一步完善四川科伦药业股份有限公司（以下简称"公司"） 的治理架构，提高公司环境、社会和治理（ESG）水平及可持续发展工作的决策 效率。根据《中华人民共和国公司法》《上市公司治理准则》及其他有关规定， 公司董事会特设立环境、社会及治理（ESG）委员会（以下简称"委员会"）， 并制定本工作细 ...